Supplemental material
Open access
4,034
Views
8
CrossRef citations to date
0
Altmetric
Coronavirus – Research Paper
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
Sakshi Bajoriaa Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
, Kawaljit Kaura Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
, Ozan S. Kumrua Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
, Greta Van Slykeb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
, Jennifer Doeringb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
, Hayley Novakb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
, Sergio A. Rodriguez Apontec Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA;d The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
, Neil C. Dalvied The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;e Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USAView further author information
, Christopher A. Naranjod The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
, Ryan S. Johnstond The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
, Judith Maxwell Silvermanf Bill & Melinda Gates Foundation, Seattle, WA, USAView further author information
, Harry Kleanthousf Bill & Melinda Gates Foundation, Seattle, WA, USAView further author information
, J. Christopher Loved The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;e Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USAView further author information
, Nicholas J. Mantisb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA
https://orcid.org/0000-0002-5083-8640View further author information
Sangeeta B. Joshia Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
& David B. Volkina Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USACorrespondence[email protected]
https://orcid.org/0000-0002-1448-1998View further author information
Article: 2079346
|
Received 25 Mar 2022, Accepted 16 May 2022, Published online: 06 Jun 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.